Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice
| Autor: | Paolo Fontana, Angela Prestifilippo, Giacomo Fisichella, Dorotea Sciacca, Gianluca Ferini, Ambrogio Gagliano, Ornella Cantale, Dario Giuffrida |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty palbociclib medicine.medical_treatment metastatic breast cancer (mbc) Review abemaciclib Palbociclib Cyclin-Dependent Kinase Inhibitors 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Medicine cyclin-dependent kinase inhibitors (CDKi) ribociclib Adverse effect Abemaciclib RC254-282 radiotherapy business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens toxicity Cell cycle medicine.disease Metastatic breast cancer Radiation therapy 030104 developmental biology chemistry 030220 oncology & carcinogenesis Toxicity business |
| Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 11 (2021) |
| ISSN: | 2234-943X |
| Popis: | Targeting cell cycle has become the gold standard for metastatic breast cancer (MBC), being cyclin-dependent kinase inhibitors (CDKIs) cornerstones of its treatment, alongside radiotherapy (RT). To date, no definite evidence regarding safety and efficacy of the combination of CDKIs plus radiotherapy (RT) is currently available. Purpose of this review is to collect data in favor or against the feasibility of the association of CDKIs + RT, describing its potential adverse events. Our review shows how CDKI + RT allows an overall satisfying disease control, proving to be effective and causing a grade of toxicity mainly influenced by the site of irradiation, leaning to favourable outcomes for sites as liver, spine or brain and to poorer outcomes for thoracic lesions or sites close to viscera; controversial evidence is instead for bone treatment. Toxicity also varies from patient to patient. To sum up, our contribution enriches and enlightens a still indefinite field regarding the feasibility of CDKIs + RT, giving cues for innovative clinical management of hormone-responsive MBC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|